[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MD3280727T2 - Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora - Google Patents

Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Info

Publication number
MD3280727T2
MD3280727T2 MDE20180158T MDE20180158T MD3280727T2 MD 3280727 T2 MD3280727 T2 MD 3280727T2 MD E20180158 T MDE20180158 T MD E20180158T MD E20180158 T MDE20180158 T MD E20180158T MD 3280727 T2 MD3280727 T2 MD 3280727T2
Authority
MD
Moldova
Prior art keywords
type
tgf
extracellular domain
beta
arm
Prior art date
Application number
MDE20180158T
Other languages
English (en)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MD3280727T2 publication Critical patent/MD3280727T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

În anumite aspecte, dezvăluirea redă complecşi polipeptidici heteromerici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor de serină/treonină kinază tip I al familiei TGF-beta sau un domeniu extracelular al unui receptor de serină/treonină kinază tip II al familiei TGF-beta. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip II selectat dintre: ActRIIA, ActRIIB, TGFBRII, BMPRII, şi MISRII. În unele modalităţi de realizare, dezvăluirea redă complecşi polipeptidici cu un singur braţ solubili care cuprind un domeniu extracelular al unui receptor tip I selectat dintre : ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, şi ALK7. Opţional complexul solubil este un heterodimer. În anumite aspecte, astfel de complecşi polipeptidici solubili se pot utiliza pentru tratamentul sau prevenirea a diferite afecţiuni asociate cu TGF-beta, incluzând fără limitare boli sau tulburări asociate cu, de exemplu, cancer, muşchi, os, grăsime, celule roşii din sânge, metabolism, fibroză şi alte ţesuturi care sunt afectate de unul sau mai mulţi liganzi ai superfamiliei TGF-beta.
MDE20180158T 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora MD3280727T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24
PCT/US2016/026275 WO2016164501A1 (en) 2015-04-06 2016-04-06 Single-arm type i and type ii receptor fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
MD3280727T2 true MD3280727T2 (ro) 2021-06-30

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20180158T MD3280727T2 (ro) 2015-04-06 2016-04-06 Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora

Country Status (21)

Country Link
US (3) US10358476B2 (ro)
EP (2) EP3280727B1 (ro)
JP (2) JP6810702B2 (ro)
KR (1) KR20170141215A (ro)
CN (3) CN113683708A (ro)
AU (2) AU2016246602B2 (ro)
CA (1) CA2981793A1 (ro)
CY (1) CY1124247T1 (ro)
DK (1) DK3280727T3 (ro)
ES (1) ES2864850T3 (ro)
HK (1) HK1252958A1 (ro)
HR (1) HRP20210411T1 (ro)
HU (1) HUE054180T2 (ro)
LT (1) LT3280727T (ro)
MA (1) MA53883A (ro)
MD (1) MD3280727T2 (ro)
PL (1) PL3280727T3 (ro)
PT (1) PT3280727T (ro)
RS (1) RS61728B1 (ro)
SI (1) SI3280727T1 (ro)
WO (1) WO2016164501A1 (ro)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
EA037293B1 (ru) 2015-04-06 2021-03-05 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
US9884900B2 (en) 2015-08-04 2018-02-06 Acceleron Pharma Inc. Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
EP3439686A4 (en) * 2016-04-06 2019-10-09 Acceleron Pharma Inc. BMPRII POLYPEPTIDES AND USES THEREOF
BR112019006918A2 (pt) 2016-10-05 2019-06-25 Acceleron Pharma Inc proteínas actriib variantes e usos das mesmas
KR20190075078A (ko) 2016-10-05 2019-06-28 악셀레론 파마 인코포레이티드 ALK4:ActRIIB 이형다량체 및 이의 용도
US11440949B2 (en) 2016-10-05 2022-09-13 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
JP7051846B2 (ja) * 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
KR20190115037A (ko) * 2017-02-01 2019-10-10 악셀레론 파마 인코포레이티드 면역 활성을 증가시키는데 이용되는 TGFβ 및 ActRII
FI3628049T3 (fi) * 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
EP3737406A4 (en) 2018-01-12 2021-11-03 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIB VARIANTS AND THEIR METHODS OF USE
WO2019157342A1 (en) * 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
WO2019213442A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
US20210213119A1 (en) * 2018-08-28 2021-07-15 Immunotech Biopharm Co., Ltd. Improved therapeutic t cell
CA3147621A1 (en) * 2019-07-18 2021-01-21 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting tgf-.beta. signaling in cd4+ helper t cells for cancer immunotherapy
WO2021119136A1 (en) * 2019-12-10 2021-06-17 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
US20230134083A1 (en) * 2020-03-13 2023-05-04 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0830459B1 (en) 1995-04-11 2007-01-24 The General Hospital Corporation Reverse two-hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
BR0008188A (pt) 1999-01-21 2002-02-13 Metamorphix Inc Inibidores de fator de diferenciação de crescimento e usos para os mesmos
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2005028517A2 (en) * 2003-05-09 2005-03-31 The General Hospital Corporation SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS
CA2539116C (en) 2003-09-15 2014-11-18 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
CN1723220A (zh) * 2003-11-13 2006-01-18 韩美药品工业株式会社 含有免疫球蛋白fc区作为载体的药物组合物
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
EA026874B1 (ru) 2005-11-23 2017-05-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
KR20170012582A (ko) * 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
EP2111229B1 (en) * 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI548647B (zh) * 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201718635A (zh) 2007-03-06 2017-06-01 安美基公司 變異之活動素受體多肽及其用途
EP2574671B1 (en) 2007-03-19 2016-02-03 National Research Council Of Canada Antagonists of ligands and uses thereof
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
US8658135B2 (en) 2008-03-19 2014-02-25 National Research Council Of Canada Antagonists of ligands and uses thereof
BRPI0911853A8 (pt) 2008-05-02 2018-03-06 Acceleron Pharma Inc composições e métodos para a modulação de angiogênese e composição de pericito
ES2852699T3 (es) 2008-06-26 2021-09-14 Acceleron Pharma Inc Antagonistas de ActRIIb y usos para aumentar los niveles de glóbulos rojos
SI3494986T1 (sl) 2008-08-14 2020-10-30 Acceleron Pharma Inc. GDF pasti
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK2370463T3 (en) * 2008-11-26 2016-11-28 Amgen Inc STABILIZED VARIANT OF activin IIB RECEPTOR
EP3702001A1 (en) 2009-03-30 2020-09-02 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056896A1 (en) 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
ES2648492T3 (es) 2012-03-28 2018-01-03 The Board Of Regents Of The University Of Texas System Fusiones de receptores TGF tipo II y tipo III
EP3036262A4 (en) * 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
WO2016090035A2 (en) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulators of activin and methods for modulating immune responses and t follicular helper cells
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
EA037293B1 (ru) 2015-04-06 2021-03-05 Акселерон Фарма Инк. Гетеромультимеры рецепторов типа i и типа ii белков суперсемейства tgf-бета
HUE054180T2 (hu) 2015-04-06 2021-08-30 Acceleron Pharma Inc Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
DK3286206T3 (da) 2015-04-22 2021-05-03 Biogen Ma Inc Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
WO2017037634A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
CA3029890A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
KR20190075078A (ko) 2016-10-05 2019-06-28 악셀레론 파마 인코포레이티드 ALK4:ActRIIB 이형다량체 및 이의 용도
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
CY1124247T1 (el) 2022-07-22
RS61728B1 (sr) 2021-05-31
JP2018517664A (ja) 2018-07-05
EP3280727B1 (en) 2021-02-17
MA53883A (fr) 2021-08-18
CN107849114B (zh) 2021-08-20
AU2021200906B2 (en) 2023-04-06
PT3280727T (pt) 2021-04-23
EP3280727A4 (en) 2019-02-13
WO2016164501A1 (en) 2016-10-13
JP7203807B2 (ja) 2023-01-13
EP3865505A1 (en) 2021-08-18
PL3280727T3 (pl) 2021-07-19
US11208460B2 (en) 2021-12-28
US10358476B2 (en) 2019-07-23
EP3280727A1 (en) 2018-02-14
ES2864850T3 (es) 2021-10-14
JP2021054839A (ja) 2021-04-08
AU2016246602B2 (en) 2020-11-19
DK3280727T3 (da) 2021-03-15
JP6810702B2 (ja) 2021-01-06
US20200055920A1 (en) 2020-02-20
HUE054180T2 (hu) 2021-08-30
CA2981793A1 (en) 2016-10-13
AU2021200906A1 (en) 2021-03-04
KR20170141215A (ko) 2017-12-22
US20220315642A1 (en) 2022-10-06
LT3280727T (lt) 2021-04-12
CN107849114A (zh) 2018-03-27
CN113683708A (zh) 2021-11-23
HK1252958A1 (zh) 2019-06-06
CN113683709A (zh) 2021-11-23
AU2016246602A1 (en) 2017-10-26
SI3280727T1 (sl) 2021-07-30
HRP20210411T1 (hr) 2021-04-30
US20160289298A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MD3280727T2 (ro) Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
MA41920A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
BR112014015105A2 (pt) inibidores da via de sinalização notch e uso do mesmo no tratamento de cânceres
EA201100355A8 (ru) Пирролопиримидины и их применение
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
ATE457311T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
CL2015001483A1 (es) Compuestos derivados de hidroxiquinolina y otros heterociclos nitrogenados, antagonistas de los receptores muscarínicos y agonistas del receptor beta2 adrenérgico; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento o prevencion del asma, bronquitis cronica o epoc.
PE20110572A1 (es) DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO INHIBIDORES DE MET
WO2015010078A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201491520A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ C-met ПРОТЕИНКИНАЗ
NO20064771L (no) 2-pyridyl substituerte imidazoler som ALK5 og/eller ALK4 inhibitorer
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
BR112015006726A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CL2014000007A1 (es) Compuestos derivados de oxazol y tiazol, inhibidores selectivos de proteinas quinasas; composicion farmaceutica; combinacion farmaceutica; su uso en el tratamiento de enfermedades tales como mastocitosis, neoplasia hematologica, trastorno mieloproliferativo, enfermedad autoinmune, enfermedad inflamatoria, alergias o enfermedad neurologica.
JP2017530372A5 (ro)
MX370789B (es) Anticuerpo anti-vegf y composición farmacéutica que comprende los mismos para usarse para prevenir, diagnosticar o tratar enfermedades relacionadas con cáncer o angiogénesis.